Cefotaxime twice daily versus ceftriaxone once daily. A randomized controlled study in patients with serious infections

B. P. Simmons, Michael Gelfand, J. Grogan, B. Craft

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We randomized 365 patients with serious infections to treatment with either 2 g intravenously (IV) cefotaxime every 12 h or 2 g IV ceftriaxone once daily. Clinical response rates were similar in both treatment groups, with success defined as satisfactory or improved response in 107 of 124 (86.3%) evaluable patients in the cefotaxime group compared with 103 of 114 (90.4%) evaluable patients in the ceftriaxone group. Bacteriologic cure rates were also similar in the two groups (86.4% in the cefotaxime group compared with 87.0% in the ceftriaxone group). There was no statistically significant difference in the incidence of drug-related adverse events in the two groups. These results indicate that 2 g cefotaxime twice daily is as effective, both clinically and bacteriologically, as 2 g ceftriaxone once daily in serious infections caused by susceptible pathogens.

Original languageEnglish (US)
Pages (from-to)155-157
Number of pages3
JournalDiagnostic Microbiology and Infectious Disease
Volume22
Issue number1-2
DOIs
StatePublished - Jan 1 1995

Fingerprint

Cefotaxime
Ceftriaxone
Infection
Drug-Related Side Effects and Adverse Reactions
Incidence
Therapeutics

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Cefotaxime twice daily versus ceftriaxone once daily. A randomized controlled study in patients with serious infections. / Simmons, B. P.; Gelfand, Michael; Grogan, J.; Craft, B.

In: Diagnostic Microbiology and Infectious Disease, Vol. 22, No. 1-2, 01.01.1995, p. 155-157.

Research output: Contribution to journalArticle

@article{6b8dc2c6e9084fd291abac5166e252ec,
title = "Cefotaxime twice daily versus ceftriaxone once daily. A randomized controlled study in patients with serious infections",
abstract = "We randomized 365 patients with serious infections to treatment with either 2 g intravenously (IV) cefotaxime every 12 h or 2 g IV ceftriaxone once daily. Clinical response rates were similar in both treatment groups, with success defined as satisfactory or improved response in 107 of 124 (86.3{\%}) evaluable patients in the cefotaxime group compared with 103 of 114 (90.4{\%}) evaluable patients in the ceftriaxone group. Bacteriologic cure rates were also similar in the two groups (86.4{\%} in the cefotaxime group compared with 87.0{\%} in the ceftriaxone group). There was no statistically significant difference in the incidence of drug-related adverse events in the two groups. These results indicate that 2 g cefotaxime twice daily is as effective, both clinically and bacteriologically, as 2 g ceftriaxone once daily in serious infections caused by susceptible pathogens.",
author = "Simmons, {B. P.} and Michael Gelfand and J. Grogan and B. Craft",
year = "1995",
month = "1",
day = "1",
doi = "10.1016/0732-8893(95)00080-T",
language = "English (US)",
volume = "22",
pages = "155--157",
journal = "Diagnostic Microbiology and Infectious Disease",
issn = "0732-8893",
publisher = "Elsevier Inc.",
number = "1-2",

}

TY - JOUR

T1 - Cefotaxime twice daily versus ceftriaxone once daily. A randomized controlled study in patients with serious infections

AU - Simmons, B. P.

AU - Gelfand, Michael

AU - Grogan, J.

AU - Craft, B.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - We randomized 365 patients with serious infections to treatment with either 2 g intravenously (IV) cefotaxime every 12 h or 2 g IV ceftriaxone once daily. Clinical response rates were similar in both treatment groups, with success defined as satisfactory or improved response in 107 of 124 (86.3%) evaluable patients in the cefotaxime group compared with 103 of 114 (90.4%) evaluable patients in the ceftriaxone group. Bacteriologic cure rates were also similar in the two groups (86.4% in the cefotaxime group compared with 87.0% in the ceftriaxone group). There was no statistically significant difference in the incidence of drug-related adverse events in the two groups. These results indicate that 2 g cefotaxime twice daily is as effective, both clinically and bacteriologically, as 2 g ceftriaxone once daily in serious infections caused by susceptible pathogens.

AB - We randomized 365 patients with serious infections to treatment with either 2 g intravenously (IV) cefotaxime every 12 h or 2 g IV ceftriaxone once daily. Clinical response rates were similar in both treatment groups, with success defined as satisfactory or improved response in 107 of 124 (86.3%) evaluable patients in the cefotaxime group compared with 103 of 114 (90.4%) evaluable patients in the ceftriaxone group. Bacteriologic cure rates were also similar in the two groups (86.4% in the cefotaxime group compared with 87.0% in the ceftriaxone group). There was no statistically significant difference in the incidence of drug-related adverse events in the two groups. These results indicate that 2 g cefotaxime twice daily is as effective, both clinically and bacteriologically, as 2 g ceftriaxone once daily in serious infections caused by susceptible pathogens.

UR - http://www.scopus.com/inward/record.url?scp=0029143460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029143460&partnerID=8YFLogxK

U2 - 10.1016/0732-8893(95)00080-T

DO - 10.1016/0732-8893(95)00080-T

M3 - Article

VL - 22

SP - 155

EP - 157

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

SN - 0732-8893

IS - 1-2

ER -